Betsy Backe, MD
Dermatology · Valdosta, GANPI 1457554131
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,215 of the $52,475 with a category attached, or 69.0%. Galderma Laboratories, L.p. accounts for 75.6% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $28,735 and has fallen 95.2% since, to $1,372 in 2025. Among dermatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $99.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$40K
- Biofrontera Inc.$3K
- AbbVie$1K
- Johnson & Johnson$1K
- Almirall LLC$876
- Regeneron Healthcare Solutions, Inc.$784
- plus $6K from 25 others
What the payments were for
- Consulting fees$8002%
- Speaking & faculty fees$36,21569%
- Travel & lodging$4,5349%
- Food & beverage$10,52620%
- Education$4001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 66 | $39,696 |
| Biofrontera Inc. | 31 | $2,732 |
| AbbVie | 75 | $1,374 |
| Johnson & Johnson | 60 | $1,162 |
| Almirall LLC | 3 | $876 |
| Regeneron Healthcare Solutions, Inc. | 38 | $784 |
| Amgen | 29 | $687 |
| Sun Pharmaceutical Industries Inc. | 24 | $665 |
| UCB, Inc. | 38 | $663 |
| Sanofi | 23 | $546 |
| Pfizer | 29 | $526 |
| Lilly USA, LLC | 22 | $469 |
| Merz North America, Inc. | 3 | $459 |
| LEO Pharma Inc. | 14 | $308 |
| Novartis | 16 | $295 |
| Dermavant Sciences, Inc. | 12 | $234 |
| E.r. Squibb & Sons, L.L.C. | 11 | $192 |
| Organogenesis Inc. | 7 | $159 |
| Incyte Corporation | 7 | $137 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Janssen Scientific Affairs, LLC | 1 | $79 |
| Genentech USA, Inc. | 4 | $64 |
| Boehringer Ingelheim | 2 | $42 |
| Dermira, Inc. | 2 | $39 |
| Revance Therapeutics, Inc. | 2 | $35 |
| Bristol Myers Squibb | 1 | $22 |
| VYNE Pharmaceuticals Inc. | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| DUSA Pharmaceuticals, Inc. | 1 | $17 |
| Strata Skin Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,475 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $225,422 |
| Dupixent PenDupilumab | 56 | $223,548 |
| TremfyaGuselkumab | 16 | $208,002 |
| RemicadeInfliximab | 12 | $198,693 |
| Enbrel SureclickEtanercept | 12 | $87,144 |
| Dupixent SyringeDupilumab | 13 | $70,808 |
| AdbryTralokinumab-Ldrm | 15 | $63,455 |
| Tacrolimus | 48 | $4,806 |
| Clobetasol Propionate | 119 | $4,134 |
| Ketoconazole | 97 | $1,866 |
| Doxycycline Hyclate | 53 | $1,597 |
| Calcipotriene | 11 | $1,470 |
| Tretinoin | 14 | $1,430 |
| Triamcinolone Acetonide | 123 | $1,107 |
| ValacyclovirValacyclovir Hcl | 55 | $1,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya, Remicade | $1,162 | $406,69528 claims |
| LEO Pharma Inc.Adbry | $308 | $63,45515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 345 dermatology providers in Georgia.
Other dermatology in Valdosta
- Firas HougeirDouglasville$3.1M
- David CohenMacon$2.9M
- Zakiya RiceAtlanta$1.1M
- Joseph PayneAtlanta$711K
- Jonathan WeissSnellville$692K
- Jamie WeismanAtlanta$620K
- Mack RachalAtlanta$260K
- Tiffany Clay-RamseyMarietta$207K
- Jessica MercerSnellville$183K
- Sumayah TaliaferroAtlanta$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.